Mutant PIK3CA controls DUSP1-dependent ERK 1/2 activity to confer response to AKT target therapy
Anuja Sathe(Stanford University), Roman Nawroth(TUM Klinikum)
Cited by 38
Related Papers
Colorectal Cancer Metastases in the Liver Establish Immunosuppressive Spatial Networking between Tumor-Associated <i>SPP1</i> + Macrophages and Fibroblasts
|Clinical Cancer Research|2022|183
S6K1 and 4E-BP1 Are Independent Regulated and Control Cellular Growth in Bladder Cancer
|PLoS ONE|2011|92
Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy
|PLoS ONE|2018|51
Functional genomics identifies predictive markers and clinically actionable resistance mechanisms to CDK4/6 inhibition in bladder cancer
|Journal of Experimental & Clinical Cancer Research|2019|34
Combination of Talazoparib and Palbociclib as a Potent Treatment Strategy in Bladder Cancer
|Journal of Personalized Medicine|2021|14